Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders
The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology and Therapy 2021-06, Vol.10 (2), p.201-209 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 209 |
|---|---|
| container_issue | 2 |
| container_start_page | 201 |
| container_title | Ophthalmology and Therapy |
| container_volume | 10 |
| creator | Chau, Charlene Y. C. Chow, Loraine L. W. Sridhar, Siddharth Shih, Kendrick C. |
| description | The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies. |
| doi_str_mv | 10.1007/s40123-021-00338-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7936587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A659925174</galeid><sourcerecordid>A659925174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-c170a77f8d3017243e440a0dba590366d57af3d7532a0d51d8e9bc2cbb06ca523</originalsourceid><addsrcrecordid>eNp9UU1v1DAUjBCIVqV_gAPykUuKP2PngrTaFlip0nKAXq0Xx9l1FduLnYBW4sdjNksFF-SDn-bNzHv2VNVrgm8IxvJd5phQVmNKaowZUzV5Vl1S0rK6EVQ9P9eKcnFRXef8iHHhK9Fy_rK6YKyRQmB1Wf3cHvbTHkYfx7hzBka0jiG73iaYXKnQEBNabx82tzVp0QMY48Kpg1xAn0tlw5TRDzft0SYMI3gPU0xHdHe06NZlC9lmBKFHq3mKzvs5nPCYyoT8qnoxwJjt9fm-qr5-uPuy_lTfbz9u1qv72gjCptoQiUHKQfUME0k5s5xjwH0HosWsaXohYWC9FIwWVJBe2bYz1HQdbgwIyq6q94vvYe687U3ZOcGoD8l5SEcdwel_O8Ht9S5-17JljVCyGLw9G6T4bbZ50t5lY8cRgo1z1pS3iismGSvUm4W6g9FqF4ZYHE05vfXOxGAHV_BVI9qWCiJ5EdBFYFLMOdnhaS-C9e-o9RK1LlHrU9SaFNGbv1_0JPkTbCGwhZBLK-xs0o9xTqH88v9sfwEfq7YZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2498483733</pqid></control><display><type>article</type><title>Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Springer Nature OA Free Journals</source><creator>Chau, Charlene Y. C. ; Chow, Loraine L. W. ; Sridhar, Siddharth ; Shih, Kendrick C.</creator><creatorcontrib>Chau, Charlene Y. C. ; Chow, Loraine L. W. ; Sridhar, Siddharth ; Shih, Kendrick C.</creatorcontrib><description>The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies.</description><identifier>ISSN: 2193-8245</identifier><identifier>EISSN: 2193-6528</identifier><identifier>DOI: 10.1007/s40123-021-00338-1</identifier><identifier>PMID: 33675508</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Care and treatment ; Commentary ; COVID-19 and its Implications for Ophthalmology ; Immunocompromised host ; Internal Medicine ; Management ; Medicine ; Medicine & Public Health ; Ophthalmology ; Uveitis ; Vaccination</subject><ispartof>Ophthalmology and Therapy, 2021-06, Vol.10 (2), p.201-209</ispartof><rights>The Author(s) 2021</rights><rights>COPYRIGHT 2021 Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-c170a77f8d3017243e440a0dba590366d57af3d7532a0d51d8e9bc2cbb06ca523</citedby><cites>FETCH-LOGICAL-c513t-c170a77f8d3017243e440a0dba590366d57af3d7532a0d51d8e9bc2cbb06ca523</cites><orcidid>0000-0001-6255-2941</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936587/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936587/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33675508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chau, Charlene Y. C.</creatorcontrib><creatorcontrib>Chow, Loraine L. W.</creatorcontrib><creatorcontrib>Sridhar, Siddharth</creatorcontrib><creatorcontrib>Shih, Kendrick C.</creatorcontrib><title>Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders</title><title>Ophthalmology and Therapy</title><addtitle>Ophthalmol Ther</addtitle><addtitle>Ophthalmol Ther</addtitle><description>The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies.</description><subject>Care and treatment</subject><subject>Commentary</subject><subject>COVID-19 and its Implications for Ophthalmology</subject><subject>Immunocompromised host</subject><subject>Internal Medicine</subject><subject>Management</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Uveitis</subject><subject>Vaccination</subject><issn>2193-8245</issn><issn>2193-6528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9UU1v1DAUjBCIVqV_gAPykUuKP2PngrTaFlip0nKAXq0Xx9l1FduLnYBW4sdjNksFF-SDn-bNzHv2VNVrgm8IxvJd5phQVmNKaowZUzV5Vl1S0rK6EVQ9P9eKcnFRXef8iHHhK9Fy_rK6YKyRQmB1Wf3cHvbTHkYfx7hzBka0jiG73iaYXKnQEBNabx82tzVp0QMY48Kpg1xAn0tlw5TRDzft0SYMI3gPU0xHdHe06NZlC9lmBKFHq3mKzvs5nPCYyoT8qnoxwJjt9fm-qr5-uPuy_lTfbz9u1qv72gjCptoQiUHKQfUME0k5s5xjwH0HosWsaXohYWC9FIwWVJBe2bYz1HQdbgwIyq6q94vvYe687U3ZOcGoD8l5SEcdwel_O8Ht9S5-17JljVCyGLw9G6T4bbZ50t5lY8cRgo1z1pS3iismGSvUm4W6g9FqF4ZYHE05vfXOxGAHV_BVI9qWCiJ5EdBFYFLMOdnhaS-C9e-o9RK1LlHrU9SaFNGbv1_0JPkTbCGwhZBLK-xs0o9xTqH88v9sfwEfq7YZ</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Chau, Charlene Y. C.</creator><creator>Chow, Loraine L. W.</creator><creator>Sridhar, Siddharth</creator><creator>Shih, Kendrick C.</creator><general>Springer Healthcare</general><general>Springer</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6255-2941</orcidid></search><sort><creationdate>20210601</creationdate><title>Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders</title><author>Chau, Charlene Y. C. ; Chow, Loraine L. W. ; Sridhar, Siddharth ; Shih, Kendrick C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-c170a77f8d3017243e440a0dba590366d57af3d7532a0d51d8e9bc2cbb06ca523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Commentary</topic><topic>COVID-19 and its Implications for Ophthalmology</topic><topic>Immunocompromised host</topic><topic>Internal Medicine</topic><topic>Management</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Uveitis</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chau, Charlene Y. C.</creatorcontrib><creatorcontrib>Chow, Loraine L. W.</creatorcontrib><creatorcontrib>Sridhar, Siddharth</creatorcontrib><creatorcontrib>Shih, Kendrick C.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ophthalmology and Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chau, Charlene Y. C.</au><au>Chow, Loraine L. W.</au><au>Sridhar, Siddharth</au><au>Shih, Kendrick C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders</atitle><jtitle>Ophthalmology and Therapy</jtitle><stitle>Ophthalmol Ther</stitle><addtitle>Ophthalmol Ther</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>10</volume><issue>2</issue><spage>201</spage><epage>209</epage><pages>201-209</pages><issn>2193-8245</issn><eissn>2193-6528</eissn><abstract>The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>33675508</pmid><doi>10.1007/s40123-021-00338-1</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6255-2941</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2193-8245 |
| ispartof | Ophthalmology and Therapy, 2021-06, Vol.10 (2), p.201-209 |
| issn | 2193-8245 2193-6528 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7936587 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Springer Nature OA Free Journals |
| subjects | Care and treatment Commentary COVID-19 and its Implications for Ophthalmology Immunocompromised host Internal Medicine Management Medicine Medicine & Public Health Ophthalmology Uveitis Vaccination |
| title | Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ophthalmological%20Considerations%20for%20COVID-19%20Vaccination%20in%20Patients%20with%20Inflammatory%20Eye%20Diseases%20and%20Autoimmune%20Disorders&rft.jtitle=Ophthalmology%20and%20Therapy&rft.au=Chau,%20Charlene%20Y.%20C.&rft.date=2021-06-01&rft.volume=10&rft.issue=2&rft.spage=201&rft.epage=209&rft.pages=201-209&rft.issn=2193-8245&rft.eissn=2193-6528&rft_id=info:doi/10.1007/s40123-021-00338-1&rft_dat=%3Cgale_pubme%3EA659925174%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2498483733&rft_id=info:pmid/33675508&rft_galeid=A659925174&rfr_iscdi=true |